| Assessment Status | NCPE Assessment process complete |
| HTA ID | - |
| Drug | Carfilzomib (in combination with lenalidomide and dexamethasone) |
| Brand | Kyprolis® |
| Indication | For the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
| Assessment Process | |
| Rapid review commissioned | 07/12/2015 |
| Rapid review completed | 06/01/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 24/03/2016 |
| NCPE assessment outcome | Reimbursement Not Recommended |
The HSE has approved reimbursement following confidential price negotiations September 2018
